{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"19.6","upperLimit":"35.2","value":"26.9"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"134"}],"units":"Participants"}],"description":"Percentage of patients with at least one evaluable FR+ ovarian cancer lesion confirmed by central pathology (Standard of truth) that was detected using the combination of OTL38 and fluorescent light but not under normal light or palpation (Full Analysis Set)","dispersionType":"95% Confidence Interval","groups":[{"description":"Patients exposed to OTL38 and who were randomly assigned to undergo NIR fluorescent imaging (OTL38+imaging) and who:\n\n* Were evaluated under both normal light and NIR fluorescent light imaging\n* Had central pathology and histology confirmation for at least one FR+ ovarian cancer lesion detected under normal light or NIR fluorescent light imaging","id":"OG000","title":"Full Analysis Set"}],"paramType":"NUMBER","reportingStatus":"POSTED","timeFrame":"30 days","title":"Efficacy Patient Level","type":"PRIMARY","unitOfMeasure":"percentage of participants"}